Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...
Q4 2025 Earnings Call February 24, 2026 8:00 AM ESTCompany ParticipantsJeff Boyle - Vice President of Investor RelationsRandy Teel ...
Gelatine Sculpt is a liquid dietary supplement positioned as a premium, holistic evolution of the gelatin trick. Marketed as a "Bariatric Jelly" alternative, Gelatine Sculpt is designed to be taken as ...
As artificial intelligence (AI) evolves beyond generative chat systems into agentic AI capable of autonomous action, a critical bottleneck has emerged: the lack of high-fidelity, real-time input ...
We look forward to sharing additional Phase 1/2 data next week at the Muscular Dystrophy Association's annual meeting and ...
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.
EAE-induced neuroinflammation. Using immuohistochemistry, flow cytometry, and single-cell RNAseq of doublets to interrogate cell-cell interactions, the authors provide solid evidence that macrophages, ...
Emerging evidence suggests widely used metabolic drugs could influence brain aging pathways, yet large clinical trials are still needed to confirm whether they truly alter the course of ...
Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 9:20 AM ESTCompany ParticipantsDavid Happel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results